<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719158</url>
  </required_header>
  <id_info>
    <org_study_id>201-201508</org_study_id>
    <nct_id>NCT02719158</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of OTO-201 in AOMT</brief_title>
  <official_title>A 1-Month, Prospective, Multicenter, Randomized, Dose-Ranging, Sham-Controlled, Blinded Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose Ranging Study of OTO-201 in AOMT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 1-month, prospective, multicenter, randomized, dose-ranging, sham-controlled,&#xD;
      blinded study in which eligible subjects with either unilateral or bilateral acute otitis&#xD;
      media with tympanostomy tubes (AOMT) will receive a single administration of 6 mg OTO-201, 12&#xD;
      mg OTO-201, or sham into the affected ear(s).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Number of subjects with adverse events during the study from dosing up to 1 month after dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examination: Auricle and Meatus</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Number of affected ears (i.e., those ears that were infected) whose external ear and ear canal (auricle and meatus), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The auricle and meatus of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the auricle and meatus with treatment (i.e., a safety measure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examination: Tympanic Membrane</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Number of affected ears (i.e., those ears that were infected) whose ear drum (tympanic membrane), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The tympanic membrane of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the tympanic membrane with treatment (i.e., a safety measure).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Otorrhea</measure>
    <time_frame>Up to Two Weeks</time_frame>
    <description>Absence of otorrhea (middle ear drainage)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Acute Otitis Media</condition>
  <condition>AOMT</condition>
  <arm_group>
    <arm_group_label>6 mg OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mg OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham (empty syringe)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 mg ciprofloxacin</intervention_name>
    <description>Single administration of OTO-201</description>
    <arm_group_label>6 mg OTO-201</arm_group_label>
    <other_name>OTIPRIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 mg ciprofloxacin</intervention_name>
    <description>Single administration of OTO-201</description>
    <arm_group_label>12 mg OTO-201</arm_group_label>
    <other_name>OTIPRIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <arm_group_label>Sham (empty syringe)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject is a male or female aged 6 months to 17 years, inclusive&#xD;
&#xD;
          -  Subject has a clinical diagnosis of acute otitis media with tympanostomy tubes (AOMT)&#xD;
&#xD;
          -  Subject's caregiver is willing to comply with the protocol an attend all study visits&#xD;
&#xD;
        Exclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject has a history of sensorineural hearing loss&#xD;
&#xD;
          -  Subject has tympanic membrane perforation other than the surgical tympanostomy tube&#xD;
             perforation&#xD;
&#xD;
          -  Subject has a history of known immunodeficiency disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl LeBel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Otonomy, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Otonomy call center for trial locations</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute otitis media with tympanostomy tubes</keyword>
  <keyword>OTIPRIO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="P2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Sham Control: simulated, single administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>95 subjects randomized (19 sham, 38 6mg, 3812mg OTO-201). 1 sham and 1 6mg subject positive for Group A strep and not in intento to treat (ITT) population (Baseline and efficacy) leaving 18 sham, 37-6mg OTO-201, 38-12 mg OTO-201 in ITT. Safety population (AE/SAE) = randomized (19 sham, 38 6mg, 38 12mg).</population>
      <group_list>
        <group group_id="B1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="B2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Sham Control: simulated, single administration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.004" spread="3.0546"/>
                    <measurement group_id="B2" value="3.955" spread="2.9111"/>
                    <measurement group_id="B3" value="3.551" spread="2.4583"/>
                    <measurement group_id="B4" value="3.498" spread="2.8915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Number of subjects with adverse events during the study from dosing up to 1 month after dosing</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Safety analysis set: all subjects who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Sham Control: simulated, single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Number of subjects with adverse events during the study from dosing up to 1 month after dosing</description>
          <population>Safety analysis set: all subjects who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Otoscopic Examination: Auricle and Meatus</title>
        <description>Number of affected ears (i.e., those ears that were infected) whose external ear and ear canal (auricle and meatus), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The auricle and meatus of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the auricle and meatus with treatment (i.e., a safety measure).</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Safety Population (19 sham, 38 6mg, 38 12 mg) who could have had one or 2 affected ears at Baseline (that is, it was not necessary for both ears to be infected to take part in the study). This is why the number of ears in each group do not equal twice the number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Sham Control: simulated, single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Otoscopic Examination: Auricle and Meatus</title>
          <description>Number of affected ears (i.e., those ears that were infected) whose external ear and ear canal (auricle and meatus), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The auricle and meatus of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the auricle and meatus with treatment (i.e., a safety measure).</description>
          <population>Safety Population (19 sham, 38 6mg, 38 12 mg) who could have had one or 2 affected ears at Baseline (that is, it was not necessary for both ears to be infected to take part in the study). This is why the number of ears in each group do not equal twice the number of participants.</population>
          <units>abnormal affected ears at Day 29</units>
          <param>Number</param>
          <units_analyzed>normal affected ears at Baseline</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>normal affected ears at Baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Otoscopic Examination: Tympanic Membrane</title>
        <description>Number of affected ears (i.e., those ears that were infected) whose ear drum (tympanic membrane), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The tympanic membrane of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the tympanic membrane with treatment (i.e., a safety measure).</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Safety Population (19 sham, 38 6mg, 38 12 mg) who could have had one or 2 affected ears at Baseline (that is, it was not necessary for both ears to be infected to take part in the study). This is why the number of ears in each group do not equal twice the number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Sham Control: simulated, single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Otoscopic Examination: Tympanic Membrane</title>
          <description>Number of affected ears (i.e., those ears that were infected) whose ear drum (tympanic membrane), when examined through an otoscope, appeared normal at Baseline and appeared abnormal at Day 29. The tympanic membrane of each infected ear was examined using an otoscope and was assessed as either normal or abnormal at every visit. This outcome looks to see if there was a worsening of the condition of the tympanic membrane with treatment (i.e., a safety measure).</description>
          <population>Safety Population (19 sham, 38 6mg, 38 12 mg) who could have had one or 2 affected ears at Baseline (that is, it was not necessary for both ears to be infected to take part in the study). This is why the number of ears in each group do not equal twice the number of participants.</population>
          <units>abnormal ears at Day 29</units>
          <param>Number</param>
          <units_analyzed>normal affected ears at Baseline</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>normal affected ears at Baseline</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Otorrhea</title>
        <description>Absence of otorrhea (middle ear drainage)</description>
        <time_frame>Up to Two Weeks</time_frame>
        <population>Modified intent-to-treat analysis set: all subjects who were randomized, received treatment, did not have group A streptococci cultured on Visit 1 (Day 1), and had at least 1 on-therapy visit.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration of OTO-201</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Sham Control: simulated, single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Otorrhea</title>
          <description>Absence of otorrhea (middle ear drainage)</description>
          <population>Modified intent-to-treat analysis set: all subjects who were randomized, received treatment, did not have group A streptococci cultured on Visit 1 (Day 1), and had at least 1 on-therapy visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported during dosing and up to 1 month following dosing.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="E2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration of OTO-201</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Sham Control: simulated, single administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication subject to Sponsor consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Otonomy, Inc.</organization>
      <phone>1-800-826-6411</phone>
      <email>medinfo@otonomy.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

